Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00423306 | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jan 18, 2007 | Alaunos Therapeutics | Study closed after Stage 1 (15 of 40 planned patients treated) due to lack of treatment response;… | Other (stated, no rule matched) |
| NCT01555710 | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy… | Phase 3 | terminated | Mar 15, 2012 | Alaunos Therapeutics | Sponsor closed enrollment in April 2013 following a change in the palifosfamide development plan… | Safety / toxicity |
| NCT03906071 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced…(SAPPHIRE) | Phase 3 | terminated | Apr 8, 2019 | Mirati Therapeutics Inc. | Inability to meet protocol objectives | Other (stated, no rule matched) |
| NCT04789096 | Tucatinib Together With Pembrolizumab and Trastuzumab(TUGETHER) | Phase 2 | terminated | Mar 9, 2021 | Breast Cancer Trials, Australia and New Zealand | Stopped on the recommendation of the BCT Independent Data and Monitoring Committee | Other (stated, no rule matched) |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or…(PINNACLE) | Phase 3 | suspended | May 18, 2022 | Spectrum Pharmaceuticals, Inc | The study has not enrolled any patients. The study design is under discussion and will likely be… | Enrollment / accrual |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With… | Phase 1 / Phase 2 | suspended | Dec 8, 2022 | National Cancer Institute (NCI) | Revisions to eligibility/design being made prior to enrollment of first participants. | Enrollment / accrual |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… | Phase 1 / Phase 2 | suspended | Nov 19, 2024 | National Cancer Institute (NCI) | Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody… | Enrollment / accrual |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… | Phase 2 / Phase 3 | suspended | May 27, 2020 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT06505018 | Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients…(ALTERNATIVE) | N/A | terminated | Jul 17, 2024 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment. | Enrollment / accrual |
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | N/A | suspended | Aug 9, 2018 | Weill Medical College of Cornell University | Study is paused for interim analysis. | Efficacy / futility |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants… | Phase 3 | terminated | Feb 6, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | Phase 2 | terminated | May 28, 2020 | Centre hospitalier de l'Université de Montréal (CHUM) | Poor accrual | Enrollment / accrual |
| NCT03108495 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients… | Phase 2 | terminated | Apr 11, 2017 | Iovance Biotherapeutics, Inc. | After reviewing available safety and efficacy data to date, Iovance concluded the study reached the… | Safety / toxicity |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation… | Phase 1 / Phase 2 | suspended | Aug 28, 2019 | National Cancer Institute (NCI) | Other - To assess the study's feasibility. | Other (stated, no rule matched) |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression… | Phase 2 | terminated | Apr 11, 2025 | Shanghai Junshi Bioscience Co., Ltd. | The research and development strategy was adjusted, so the research was suspended | Sponsor / business decision |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular… | Phase 2 | terminated | Sep 30, 2020 | Mayo Clinic | grant and funding expired | Funding |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | — | terminated | Oct 12, 2022 | Mayo Clinic | Slow accrual; lack of eligible study participants | Enrollment / accrual |
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative… | Phase 2 | withdrawn | Mar 4, 2024 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of… | Phase 2 | withdrawn | Mar 22, 2022 | Fifth Affiliated Hospital, Sun Yat-Sen University | The study was terminated because the protocol was upgraded after being considered insufficiently… | Other (stated, no rule matched) |
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated…(G360-IIT) | Phase 2 | terminated | Feb 6, 2023 | Hackensack Meridian Health | Slow Accrual | Enrollment / accrual |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | Phase 1 | terminated | Nov 4, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug… | Phase 2 | suspended | Jun 15, 2023 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT01720186 | Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions…(SPI COHERENCE) | N/A | terminated | Nov 2, 2012 | Institut Claudius Regaud | not stated | Not stated |
| NCT04047693 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | Phase 2 | terminated | Aug 7, 2019 | Pusan National University Yangsan Hospital | Poor accrual due to increased use of alternative neoadjuvant treatment options. | Enrollment / accrual |
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian… | Phase 1 | terminated | Nov 3, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell… | Phase 1 | suspended | Sep 27, 2024 | Dwight Owen | Pending ICF update | Other (stated, no rule matched) |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475)… | Phase 3 | terminated | Feb 4, 2021 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05937074 | Metabolic Response to Food in Lung Cancer(METRIC) | — | terminated | Jul 10, 2023 | Pennington Biomedical Research Center | Poor accrual. | Enrollment / accrual |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | University of Washington | Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity… | Other (stated, no rule matched) |
| NCT07814365 | PBI for Low-risk Breast Cancer | N/A | withdrawn | Sep 11, 2026 | Fudan University | funding issue | Funding |
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA… | Phase 1 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06274034 | MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors | Early Phase 1 | terminated | Feb 23, 2024 | Mayo Clinic | Funds expired | Funding |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory,… | Phase 2 | withdrawn | Apr 24, 2025 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast… | Phase 2 / Phase 3 | suspended | Mar 13, 2017 | M.D. Anderson Cancer Center | PI Requested | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… | Phase 2 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT06722807 | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses(CASPIAN) | N/A | suspended | Dec 9, 2024 | University of Florida | Interim analysis | Efficacy / futility |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT07644702 | WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial… | N/A | terminated | Jun 12, 2026 | Mayo Clinic | Unable to reach enrollment target before the forum date of 9/17/2026 | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 1 hour agoSource updated Sep 30, 2026source: clinicaltrials